Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)

PURPOSE: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation subgroup. Broader response-predictive biomarkers are needed. We explored the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tovey, Holly, Sipos, Orsolya, Parker, Joel S., Hoadley, Katherine A., Quist, Jelmar, Kernaghan, Sarah, Kilburn, Lucy, Salgado, Roberto, Loi, Sherene, Kennedy, Richard D., Roxanis, Ioannis, Gazinska, Patrycja, Pinder, Sarah E., Bliss, Judith, Perou, Charles M., Haider, Syed, Grigoriadis, Anita, Tutt, Andrew, Cheang, Maggie Chon U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502473/
https://www.ncbi.nlm.nih.gov/pubmed/37574209
http://dx.doi.org/10.1158/1078-0432.CCR-23-0370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502473/
https://www.ncbi.nlm.nih.gov/pubmed/37574209
http://dx.doi.org/10.1158/1078-0432.CCR-23-0370

Ejemplares similares